QR-koda

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib

BackgroundSunitinib is approved for the treatment of metastatic renal cell carcinoma (mRCC), imatinib-resistant gastrointestinal stromal tumors (GIST), and advanced pancreatic neuroendocrine tumors (PNET). This study aims to investigate the safety profiles of sunitinib through data mining of the US...

Olles dieđut

Furkejuvvon:
Váldodahkkit: Xusheng Zhang, Xiuli Ren, Tianyu Zhu, Wanjin Zheng, Chengwu Shen, Cuicui Lu
Materiálatiipa: Artigo
Giella:Inglês
Almmustuhtton: Frontiers Media S.A. 2024-07-01
Ráidu:Frontiers in Pharmacology
Fáttát:
sunitinib
FDA adverse event reporting system
disproportionality analyses
pharmacovigilance
adverse event
Liŋkkat:https://www.frontiersin.org/articles/10.3389/fphar.2024.1407709/full
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid